Delaware Jury Awards Beckman Coulter $56M in Cytek Patent Case

A Delaware federal jury determined that Cytek Biosciences’ products for analyzing single-cell blood and tissue samples infringe a patent owned by Beckman Coulter, awarding the plaintiff $56 million in damages. The verdict was returned on August 20, 2026.

The case centers on cell-analysis technology used in life sciences research and diagnostics. Beckman Coulter alleged that Cytek’s instruments and reagents infringed its patented methods for high-parameter flow cytometry.

The jury’s decision follows trial proceedings in the U.S. District Court for the District of Delaware. No immediate post-trial motions or appeals have been reported.

The outcome highlights ongoing litigation in the competitive field of flow cytometry instrumentation and reagents.

Sources: https://www.reuters.com/legal/intellectual-property/ https://www.law360.com/ip/news